Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
$1.33
+2.3%
$1.32
$1.05
$10.00
$41.84M1.66172,956 shs3.44 million shs
Lifevantage Corporation stock logo
LFVN
Lifevantage
$12.11
-10.0%
$13.14
$8.17
$27.38
$152.44M0.39100,975 shs473,727 shs
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
$19.36
+3.0%
$15.08
$6.53
$26.40
$169.49M0.15107,254 shs91,159 shs
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
$6.68
+2.5%
$7.13
$4.44
$11.80
$170.05M-0.2776,513 shs50,730 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
+2.31%-0.75%+3.10%-1.48%-83.78%
Lifevantage Corporation stock logo
LFVN
Lifevantage
-10.03%-7.56%-6.41%-3.27%+37.93%
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
+2.98%+2.22%+40.49%+135.24%+18.09%
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
+2.45%+1.83%+3.41%-24.52%+1.06%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
$1.33
+2.3%
$1.32
$1.05
$10.00
$41.84M1.66172,956 shs3.44 million shs
Lifevantage Corporation stock logo
LFVN
Lifevantage
$12.11
-10.0%
$13.14
$8.17
$27.38
$152.44M0.39100,975 shs473,727 shs
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
$19.36
+3.0%
$15.08
$6.53
$26.40
$169.49M0.15107,254 shs91,159 shs
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
$6.68
+2.5%
$7.13
$4.44
$11.80
$170.05M-0.2776,513 shs50,730 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
+2.31%-0.75%+3.10%-1.48%-83.78%
Lifevantage Corporation stock logo
LFVN
Lifevantage
-10.03%-7.56%-6.41%-3.27%+37.93%
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
+2.98%+2.22%+40.49%+135.24%+18.09%
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
+2.45%+1.83%+3.41%-24.52%+1.06%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
3.00
Buy$15.501,065.41% Upside
Lifevantage Corporation stock logo
LFVN
Lifevantage
3.00
Buy$30.50151.86% Upside
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
1.75
Reduce$73.67280.51% Upside
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
3.00
Buy$15.33129.54% Upside

Current Analyst Ratings Breakdown

Latest ACRV, NVCT, MCRB, and LFVN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/14/2025
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$9.00 ➝ $8.00
8/4/2025
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$15.00 ➝ $10.00
(Data available from 9/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
N/AN/AN/AN/A$5.68 per shareN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$228.53M0.67$0.88 per share13.73$2.05 per share5.91
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
$126.32M1.34N/AN/A$1.61 per share12.02
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
N/AN/AN/AN/A$0.50 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
-$80.56M-$2.25N/AN/AN/AN/A-50.78%-46.08%11/12/2025 (Estimated)
Lifevantage Corporation stock logo
LFVN
Lifevantage
$2.94M$0.7416.36N/A4.29%34.88%15.42%11/4/2025 (Estimated)
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
$140K-$4.60N/AN/AN/AN/A-350.16%-67.69%11/12/2025 (Estimated)
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
-$19M-$1.17N/AN/AN/AN/A-150.81%-94.84%11/4/2025 (Estimated)

Latest ACRV, NVCT, MCRB, and LFVN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
9/4/2025Q4 2025
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.17$0.17N/A$0.15$57.93 million$55.11 million
8/13/2025Q2 2025
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
-$0.57-$0.55+$0.02-$0.55N/AN/A
8/6/2025Q2 2025
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
-$2.72-$2.27+$0.45-$2.27$11.75 millionN/A
8/5/2025Q2 2025
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
-$0.25-$0.30-$0.05-$0.30N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
N/AN/AN/AN/AN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.181.49%N/A24.32%3 Years
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
N/AN/AN/AN/AN/A
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
N/AN/AN/AN/AN/A

Latest ACRV, NVCT, MCRB, and LFVN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/26/2025
Lifevantage Corporation stock logo
LFVN
Lifevantage
quarterly$0.04501.37%9/8/20259/8/20259/16/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
N/A
10.31
10.31
Lifevantage Corporation stock logo
LFVN
Lifevantage
N/A
1.66
0.98
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
N/A
1.57
1.57
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
N/A
2.66
2.66

Institutional Ownership

CompanyInstitutional Ownership
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
71.62%
Lifevantage Corporation stock logo
LFVN
Lifevantage
35.32%
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
59.34%
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
96.77%

Insider Ownership

CompanyInsider Ownership
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
11.90%
Lifevantage Corporation stock logo
LFVN
Lifevantage
20.65%
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
4.70%
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
30.52%
CompanyEmployeesShares OutstandingFree FloatOptionable
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
5831.46 million27.71 millionNot Optionable
Lifevantage Corporation stock logo
LFVN
Lifevantage
26012.59 million9.99 millionOptionable
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
3308.75 million8.34 millionOptionable
Nuvectis Pharma, Inc. stock logo
NVCT
Nuvectis Pharma
825.46 million17.69 millionNot Optionable

Recent News About These Companies

Nuvectis Pharma, Inc.
Nuvectis (NVCT) Q2 Loss Widens 43%
Nuvectis Pharma Inc News (NVCT) - Investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Acrivon Therapeutics stock logo

Acrivon Therapeutics NASDAQ:ACRV

$1.33 +0.03 (+2.31%)
Closing price 09/5/2025 04:00 PM Eastern
Extended Trading
$1.87 +0.54 (+40.90%)
As of 09/5/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.

Lifevantage stock logo

Lifevantage NASDAQ:LFVN

$12.11 -1.35 (-10.03%)
Closing price 09/5/2025 04:00 PM Eastern
Extended Trading
$12.35 +0.24 (+1.98%)
As of 09/5/2025 07:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.

Seres Therapeutics stock logo

Seres Therapeutics NASDAQ:MCRB

$19.36 +0.56 (+2.98%)
Closing price 09/5/2025 04:00 PM Eastern
Extended Trading
$19.32 -0.04 (-0.23%)
As of 09/5/2025 05:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Nuvectis Pharma stock logo

Nuvectis Pharma NASDAQ:NVCT

$6.68 +0.16 (+2.45%)
Closing price 09/5/2025 04:00 PM Eastern
Extended Trading
$6.70 +0.02 (+0.30%)
As of 09/5/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.